Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miokamycin). Part III-3. Chronic toxicity in beagle dogs: 26-week-treatment in female dogs.
Miokamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens. The objective of this study was to determine the chronic toxicity of MOM in female Beagle dogs after once daily repeated p.o. administration of MOM, non-crystalline solid, for 26 weeks at daily dosages of 100, 200 and 400 mg/kg. It is concluded that MOM, non-crystalline solid, did not show any toxic effects in this study and the maximum non-toxic dose is presumed to be 400 mg/kg or more in female Beagle dogs administered once daily for 26 weeks.
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D004285:Dogs; D004721:Endoplasmic Reticulum / Q000648:ultrastructure; D005260:Female; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007933:Leucomycins / Q000633:toxicity*; D008099:Liver / Q000648:ultrastructure; D015644:Miocamycin; D013223:Statistics as Topic
D007933:Leucomycins; D015644:Miocamycin; D007770:L-Lactate Dehydrogenase; D000410:Alanine Transaminase